JPL Wealth Management’s Fulcrum Therapeutics FULC Stock Holding History

JPL Wealth Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17	Closed	-$131	–	1910
2026 Q1	$131	Buy	+17	New	+$158	﹤0.01%	1448

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JPL Wealth Management's FULC Position: Q2 2026 in Review

JPL Wealth Management sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 17 shares — an estimated $131 sold.

JPL Wealth Management first reported a position in FULC in Q1 2026 and held it in 1 quarter. The position peaked at $131 in Q1 2026. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

JPL Wealth Management reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
JPL Wealth Management sold 17 Fulcrum Therapeutics shares in Q2 2026, an estimated $131.
JPL Wealth Management first reported a position in Fulcrum Therapeutics in Q1 2026 and held it in 1 quarter.
JPL Wealth Management's Fulcrum Therapeutics position peaked at $131 in Q1 2026.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on JPL Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.